

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

**PHA 5127**

**Final Exam  
Fall 2000**

On my honor, I have neither given nor received unauthorized aid in doing this assignment.

---

Name \_\_\_\_\_

Question/Points

1. \_\_\_\_\_ /15 pts
  2. \_\_\_\_\_ /15 pts
  3. \_\_\_\_\_ /15 pts
  4. \_\_\_\_\_ /20 pts
  5. \_\_\_\_\_ /15 pts
  6. \_\_\_\_\_ /15 pts
  7. \_\_\_\_\_ /45 pts
  8. \_\_\_\_\_ /15 pts
  9. \_\_\_\_\_ /15 pts
  10. \_\_\_\_\_ /15 pts
  11. \_\_\_\_\_ /15 pts
  12. \_\_\_\_\_ /15 pts (Bonus)
- TOTAL \_\_\_\_\_ /200 (215)

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

1. The terminal half-life after i.v. administration of the opioid peptide dynorphin is less than one minute. When inhaled the terminal half-life is 5 minutes. When given intramuscularly the terminal half-life is 25 minutes. Explain! (15 points)

- 2.) Explain why for a two-compartmental model, the  $Vd_{area} = Vd_{\beta}$  depends on clearance (15 points):  $Vd_{area} = CL/\beta$

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

3. (15 points)

Explain the meaning of the blocked parts of the equation.

$$Cp_{\min} = \boxed{\frac{D}{V_d}} \cdot \boxed{\frac{1}{1 - e^{-k_e \cdot \tau}}} \cdot \boxed{e^{-k_e \cdot \tau}}$$

$$\frac{D}{V_d}$$


$$\frac{1}{1 - e^{-k_e \cdot \tau}}$$

$$e^{-k_e \cdot \tau}$$

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

4. The following concentration time profiles were observed after multiple bolus injections of a drug. The two curves differ in one of the input parameters (Dose, CL or Vd). (20 pts).



\*Average steady-state concentration

Identify the input parameter that differs.

Explain in one or two sentences your reasoning.

What is the numeric value of this parameter?

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

5. A lipophilic, neutral, **high** extraction drug (cleared only by the liver) is given to two patients by constant rate infusion (not multiple (intermittent) short term infusions). Steady state has been reached. Patient 1 shows a plasma protein binding of 20% for this drug ( $f_u = 0.8$ ). Patient 2 shows a plasma protein binding of 60% for this drug ( $f_u = 0.4$ ). (15 pts)

Fill in the blanks for the following statements (**always compare patient 1 and 2, you might want to use the terms “larger than”, “smaller than”, “the same as”**):

- a) The volume of distribution of drug A in patient 1 is \_\_\_\_\_ the volume of distribution in patient 2.
- b) The clearance of drug A in patient 1 is \_\_\_\_\_ the clearance in patient 2.
- c) Applying the same dose to patient 1 and 2 will result in a steady state plasma level in Patient 1 that is \_\_\_\_\_ that in patient 2
- d) Applying the same dose to patient 1 and 2 will result in a free steady- state plasma level in Patient 1 that is \_\_\_\_\_ that in patient 2.
- e) To achieve the same **free** plasma steady state concentrations, the daily dose in patient 1 should be \_\_\_\_\_ that in patient 2.

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

6. A lipophilic, neutral, **low** extraction drug (cleared only by the liver) is given to two patients by constant rate infusion (not multiple short term infusions). Steady state has been reached. Patient 1 shows a plasma protein binding of 20% for this drug ( $f_u = 0.8$ ). Patient 2 shows a plasma protein binding of 60% for this drug ( $f_u = 0.4$ ). (15 pts)

Fill in the blanks for the following statements (**always compare patient 1 and 2, you might want to use the terms “larger than”, “smaller than”, “the same as”, faster than, later than**):

- a) The volume of distribution of drug A in patient 1 is \_\_\_\_\_ the volume of distribution in patient 2.
- b) The clearance of drug A in patient 1 is \_\_\_\_\_ the clearance in patient 2.
- c) Applying the same dose patient 1 will result in a steady state plasma level in Patient 1 that is \_\_\_\_\_ that in patient 2
- d) Applying the same dose to patient 1 and 2 will result in a free steady state plasma levels in Patient 1 that is \_\_\_\_\_ that in patient 2.
- e) To achieve the same **free** plasma steady state concentrations, the  $k_o$  in patient 1 should be \_\_\_\_\_ that in patient 2.

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

- 7.) A 24-year-old female patient Noel Christmas (72 kg), is admitted to the hospital after sustaining multiple traumatic injuries. Her recovery is complicated by the onset of acute renal failure one-week after admission. During the second week she experienced a spiking fever, gram-positive bacill, resistant to methicillin but susceptible to vancomycin. The physician decides to begin a course of vancomycin. (45 points)

Assume a creatinine clearance of 125 ml/min.

The average  $V_d$  for Vancomycin is about 0.9 L/kg (based on total body weight).

$K = 0.00083 [\text{CrCL}(\text{in ml/min})] + 0.0044$  (units of  $K_e$ : 1/hr)

- a) Calculate an intravenous vancomycin loading dose to achieve a concentration of 20 mg/L achieved 2 hr after the end of a 1-hr infusion

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

- 7-b) The calculated loading dose was consequently administered to the patient. Two hours after the end of the loading dose, the vancomycin concentration was 29 mg/L; it is 17.5 mg/L at 37 hr after the end of this infusion. Assume that the plasma vancomycin concentration should decline to 10.0 mg/L before another dose is given and that the steady state plasma concentration desired 2 hr after the infusion is 20 mg/L. What would be the dosing interval  $\tau$  (from start of an infusion to the next start of the infusion) and the dose to achieve these levels at steady state?

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

8. The oral bioavailability of a **very lipophilic**, neutral, **high extraction** drug (showing linear pharmacokinetics) after oral administration of a tablet is significantly affected by: (15 pts)

- |   |                            |   |                           |
|---|----------------------------|---|---------------------------|
| A | the liver blood flow       | E | the pH of the G.I. tract. |
| B | the dose                   | F | the dissolution rate      |
| C | the plasma protein binding | G | none of the above         |
| D | the color of the tablet    |   |                           |

Select the correct answer(s) from the list above: \_\_\_\_\_

9. Which of the following factors significantly affect the renal clearance of an unionized drug that shows complete passive renal reabsorption from the “urine” back into the blood: (15 pts)

- a) plasma protein binding
- b) activity of cationic transporters in the tubuli.
- c) urine flow
- d) pH of urine
- e) liver blood flow

List the correct answer(s): \_\_\_\_\_

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

10. Mark whether the following statements are true (T) or false (F). (15 pts)
- T F Loading doses are mainly given for drugs with short half-life.
- T F A high volume of distribution will result in a high clearance
- T F If Drug A is excreted by glomerular filtration as well as by hepatic metabolism and Drug B is cleared only by hepatic clearance, then in a patient with total renal failure, total body clearance of drug A and B will be affected.
- T F The oral bioavailability of a drug is determined by the extraction ratio E.
- T F The distribution of highly lipophilic small drug molecule is perfusion rate limited.
11. The volume of distribution of an drug X is 500 L. Select which statement(s) is (are) consistent with this observation (15 pts)
- A. Plasma protein binding is more pronounced than tissue binding
- B. Tissue protein binding is more pronounced than plasma protein binding
- C. The drug is able to cross membranes
- D. Drug X can not be an acid or base as drug X is able to cross membranes
- E. The clearance of the drug has to be high, as the plasma protein binding is low

Answer(s): \_\_\_\_\_

Name: \_\_\_\_\_

SS#: \_\_\_\_\_

12) The Daily Crossword Puzzle for all you students who like puzzles and some more points (15 points). ☺  
Fill in the puzzle by completing the following statements:

DOWN

1. In the kidney, a drug may be either \_\_\_\_\_, secreted, or reabsorbed.
2. \_\_\_\_\_ is “Father Christmas” in French. (optional)
3. A two-compartment body model is required to describe the pharmacokinetic profile of a drug if the drug exhibits a pronounced \_\_\_\_\_ ( $\alpha$ ) phase.
4. A number between eight and ten; Sounds like “no” in German (optional).
5. Together, \_\_\_\_\_ and volume of distribution determine the elimination rate constant of a drug.
6. If  $k_a \ll k_e$  for a drug administered orally (typical of a sustained release formulation), the drug is said to follow “ \_\_\_\_\_ - \_\_\_\_\_ ” kinetics.

ACROSS

1. The method of residuals, also known as “ \_\_\_\_\_ ”, is means by which  $k_e$  and  $k_a$  may be separated and calculated when oral data is analyzed.
7. \_\_\_\_\_ clearance may be calculated to estimate the GFR of a patient.
8. A measure of enzyme activity in the liver is \_\_\_\_\_ clearance.
9. The \_\_\_\_\_ is the fraction of an oral dose that enters systemic circulation after administration.
10. A \_\_\_\_\_ dose is often used to reach desired steady state levels more quickly at the beginning of a multiple dosing regimen.
11. Once a constant rate infusion is started, the time required to reach steady state levels is dependent on the \_\_\_\_\_ (multiplied by 5) of the drug.

				3															
				8							5								
		2																	
1																			
										11		6							
				9															
7								4											
			10																